SANTA CRUZ BIOTECHNOLOGY, INC.

uPAR (N-19): sc-9793



BACKGROUND

Urokinase plasminogen activator receptor (uPAR), also designated CD87, is a glycoprotein I-anchored surface receptor specific for urokinase plasminogen activator (uPA). Upon binding to uPAR, uPA converts the surface bound, large serum β -globulin, plasminogen to plasmin. Plasmin, which is also designated fibrinolysin, is a trypsin-like enzyme that acts on Arg-Lys bonds and induces pericellular proteolysis in Fibrin and Fibrinogen, and thereby contributes to the systematic activation of the coagulation cascade. This pathway is observed during re-epithelialization of lesions, wound healing and tissue remodeling. uPA and uPAR are known to be overexpressed in mesenchymal and epithelial origin tumor cells and are required for tumor invasion and metastasis. Ras, MEK, ERK and MLCK function as downstream effectors in the uPAR-dependent signaling cascade, which is initiated by uPA binding, and promotes cellular migration in an integrin selective manner.

CHROMOSOMAL LOCATION

Genetic locus: PLAUR (human) mapping to 19q13.31.

SOURCE

uPAR (N-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of uPAR of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-9793 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

uPAR (N-19) is recommended for detection of uPAR of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for uPAR siRNA (h): sc-36781, uPAR shRNA Plasmid (h): sc-36781-SH and uPAR shRNA (h) Lentiviral Particles: sc-36781-V.


Molecular Weight of uPAR: 55-60 kDa.


Positive Controls: uPAR (h2): 293T Lysate: sc-170817, MCF7 whole cell lysate: sc-2206 or HeLa whole cell lysate: sc-2200.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 4) Immuno-histochemistry: use ImmunoCruz™: sc-2053 or ABC: sc-2023 goat IgG Staining Systems.

DATA





uPAR (N-19): sc-9793. Western blot analysis of uPAR expression in non-transfected: sc-117752 (**A**) and human uPAR transfected: sc-170817 (**B**) 293T whole cell lysates.

uPAR (N-19): sc-9793. Immunoperoxidase staining of formalin-fixed, paraffin-embedded human breast tumor showing membrane and cytoplasmic staining.

SELECT PRODUCT CITATIONS

- Milde-Langosch, K., et al. 2004. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res. Treat. 86: 139-152.
- Kiyan, J., et al. 2005. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β. EMBO J. 24: 1787-1797.
- Novotny, A., et al. 2010. A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29. Eur. J. Pharmacol. 646: 22-30.
- Carter, J.C., et al. 2010. Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells. J. Thromb. Haemost. 8: 1323-1332.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed

Try **uPAR (E-3): sc-376494** or **uPAR (10G7): sc-13522**, our highly recommended monoclonal alternatives to uPAR (N-19).